Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kyorin: Sales Up 13.5% Driven by Kipres
November 23, 2009
- Zeria: Sales Up Driven by OTC Drugs
November 23, 2009
- Half-year Business Results for Leading Generic Makers
November 23, 2009
- Fuso: Operating Profits Down 56.6%
November 23, 2009
- Univ. Hospitals Should Use More Generics: Mr Isobe
November 23, 2009
- Seikagaku: Sales Up 4.6% Driven by Mainstay Products
November 23, 2009
- GRU WG Reviews Gov't Projects for Saving
November 23, 2009
- Tsumura: Record-High Profits Due to Good Sales of Kampo Medicines
November 23, 2009
- Re-price Long-Listed Drugs Looking at Prices of Generics: WG
November 23, 2009
- Meiji Seika: Pharma Business Up 3.2% Driven by Generics
November 23, 2009
- No Conclusion on 2% Price Adjustment Range
November 23, 2009
- Astellas Licenses Linaclotide from Ironwood
November 23, 2009
- Chuikyo Members Split about How to Respond to GRU WG's Recommendation
November 23, 2009
- Nippon Kayaku Licenses Apaziquone from Spectrum
November 23, 2009
- FPMAJ's Proposal Is a Package Deal: Mr Hasegawa
November 23, 2009
- Top-Five Wholesalers'Operating Profits Down 19% Despite 6.6% Increase in Sales
November 23, 2009
- Mr Miura to Represent Pharmacists Because of His Business Experience at Hospital
November 23, 2009
- Banyu to Recommend Januvia in First-Line Therapy
November 23, 2009
- Novartis Applies for New-Type Influenza Vaccine
November 23, 2009
- Plavix Drives Business of sanofi-aventis in Japan: President P. Chocat
November 23, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…